Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

The new branding also precedes GSK’s proposed demerger this year, which will mean it focuses entirely on biopharma innovation, while its consumer healthcare business, Haleon ... elements of the ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Former Tesco head Sir Dave Lewis has also been named as chairman-designate of Haleon and is leading the task of assembling a board of directors for the company. GSK holds a majority controlling ...

GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion).

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK (GSK.L), opens new tab and Pfizer's consumer healthcare businesses in 2019.